Axial Spondyloarthritis

Adalimumab Continuation Linked to Fewer Flares After Remission in Nonradiographic axSpA

Adalimumab Continuation Linked to Fewer Flares After Remission in Nonradiographic axSpA

By

In patients with nonradiographic axial spondyloarthritis who achieve remission with adalimumab, continued therapy was linked to fewer flares vs treatment withdrawal.

Novel Automated Mobility Measure Yields High Reproducibility in Axial Spondyloarthritis

Novel Automated Mobility Measure Yields High Reproducibility in Axial Spondyloarthritis

By

Researchers assessed the reproducibility of UCOASMI in clinical practice settings.

Gender Differences in Axial Spondyloarthritis: Comparing Disease Burden and Treatment

Gender Differences in Axial Spondyloarthritis: Comparing Disease Burden and Treatment

By

An improved understanding of the gender differences in axial spondyloarthritis can improve disease treatment and reduce disease burden.

ASAS Health Index Valid, Reliable in Axial and Peripheral Spondyloarthritis

ASAS Health Index Valid, Reliable in Axial and Peripheral Spondyloarthritis

By

The Assessment of Spondyloarthritis International Society Health Index proved to be valid, reliable, and responsive.

Effects of Maternal axSpA Disease Activity on Pregnancy Outcomes Examined

Effects of Maternal axSpA Disease Activity on Pregnancy Outcomes Examined

By

A systematic review revealed no signal for increased pregnancy loss in patients with axial spondyloarthritis.

Ustekinumab, TNF Inhibitors Improve 6-Month Outcomes in Psoriatic Arthritis

Ustekinumab, TNF Inhibitors Improve 6-Month Outcomes in Psoriatic Arthritis

By

Researchers sought to evaluate the efficacy, tolerability, and persistence of TNFi and ustekinumab in patients with psoriatic arthritis initiating first-line, second-line, or third-line biologic DMARDs.

Reduced Structural Damage in Early Axial Spondyloarthritis Linked to Increased IL-31 Levels

Reduced Structural Damage in Early Axial Spondyloarthritis Linked to Increased IL-31 Levels

By

Increased interleukin-31 levels may protect against structural damage in patients with axial spondyloarthritis.

Extended Disease Duration Increases Risk for IBD, Uveitis in Axial Spondyloarthritis

Extended Disease Duration Increases Risk for IBD, Uveitis in Axial Spondyloarthritis

By

Axial spondyloarthritis disease duration was associated with higher risk of developing acute anterior uveitis and inflammatory bowel disease, but not psoriasis.

High Rate of Hidradenitis Suppurativa Observed in Patients With Axial Spondyloarthritis

High Rate of Hidradenitis Suppurativa Observed in Patients With Axial Spondyloarthritis

By

Hidradenitis suppurativa is more common in patients with axial spondyloarthritis compared with the general population.

Certolizumab Pegol Demonstrates Positive Results in Phase 3 Trial for Nonradiographic Axial Spondyloarthritis

Certolizumab Pegol Demonstrates Positive Results in Phase 3 Trial for Nonradiographic Axial Spondyloarthritis

By

Results from a phase 3 trial show that certolizumab pegol improves the signs and symptoms of nonradiographic axial spondyloarthritis compared with placebo at 52 weeks.

Incidence of Cardiovascular Events Similar in Rheumatoid Arthritis, Spondyloarthritis

Incidence of Cardiovascular Events Similar in Rheumatoid Arthritis, Spondyloarthritis

By

The incidence of adverse cardiovascular events in patients with RA do not differ significantly compared with those with PsA or axSpA.

Radiographic Sacroiliitis vs MRI Structural Lesions for Axial Spondyloarthritis Classification

Radiographic Sacroiliitis vs MRI Structural Lesions for Axial Spondyloarthritis Classification

By

Researchers sought to investigate the utility of adding structural MRI lesions of the sacroiliac joints to the imaging criterion of the ASAS axSpA criteria.

Sustained Clinical, Functional Improvements With Adalimumab in Axial Spondyloarthritis

Sustained Clinical, Functional Improvements With Adalimumab in Axial Spondyloarthritis

By

Results from the ABILITY-1 study show sustained clinical and functional improvements with adalimumab treatment in nonradiographic axial spondyloarthritis.

Disease Activity in Axial Spondyloarthritis Generally Low, Stable During Pregnancy

Disease Activity in Axial Spondyloarthritis Generally Low, Stable During Pregnancy

By

Researchers found that disease activity was highest during the second trimester of pregnancy.

Trabecular Bone Score May Predict Future Vertebral Fracture in Axial Spondyloarthritis

Trabecular Bone Score May Predict Future Vertebral Fracture in Axial Spondyloarthritis

By

Researchers found that trabecular bone scores may be predictive of future vertebral fractures in patients with axial spondyloarthritis.

Comorbid Fibromyalgia and Axial Spondyloarthritis: Response to TNF Blocker Therapy

Comorbid Fibromyalgia and Axial Spondyloarthritis: Response to TNF Blocker Therapy

By

Researchers sought to confirm whether concomitant fibromyalgia has a negative effect on TNF blocker response.

Adalimumab Reduces Whole-Body MRI Indices of Inflammation in axSpA

Adalimumab Reduces Whole-Body MRI Indices of Inflammation in axSpA

By

Adalimumab may decrease whole-body magnetic resonance imaging indices of inflammation in both axial and peripheral joints and enthuses in axSpA.

Anti-CD74 Antibodies Have Limited Diagnostic Value in Early Axial Spondyloarthritis

Anti-CD74 Antibodies Have Limited Diagnostic Value in Early Axial Spondyloarthritis

By

Anti-CD74 IgG and IgA antibodies have limited value in the diagnosis of early axial spondyloarthritis in younger patients who present with early back pain.

Adherence to Anti-TNF Blocker Recommendations in axSpA Linked to Improved Quality of Life

Adherence to Anti-TNF Blocker Recommendations in axSpA Linked to Improved Quality of Life

By

Adherence to recommendations for the initiation and continuation of TNF-alpha blocker therapy in patients with axial spondyloarthritis is associated with improved quality of life.

Challenges of Targeting Remission in Axial Spondyloarthritis

Challenges of Targeting Remission in Axial Spondyloarthritis

By

Current guidelines define remission as the absence of clinical and laboratory evidence of significant inflammatory disease, but the tools that are currently available are inadequate to assess clinical remission.

Functional Status in Early Axial Spondyloarthritis: The Role of Spinal Structural Damage

Functional Status in Early Axial Spondyloarthritis: The Role of Spinal Structural Damage

By

Results of the GESPIC study found that structural damage in the spine and disease activity were both determinants of functional status and spine mobility in patients with early axial spondyloarthritis.

Sustained Reduction in axSpA Joint Inflammation With Certolizumab Pegol

Sustained Reduction in axSpA Joint Inflammation With Certolizumab Pegol

By

Decreases in spinal and sacroiliac joint inflammation on MRI were maintained through 204 weeks with certolizumab pegol treatment.

Diagnostic Value of Repeat MRI in Suspected Early Axial Spondyloarthritis

Diagnostic Value of Repeat MRI in Suspected Early Axial Spondyloarthritis

By

The diagnostic utility of repeat MRI was examined in people who were HLA-B27-negative or positive.

Axial Spondyloarthritis Classification: Assessing Need for Spine MRI

Axial Spondyloarthritis Classification: Assessing Need for Spine MRI

By

Researchers recommended against including MRI in the Assessment of Spondyloarthritis International Society classification criteria for axial spondyloarthritis.

ASAS/EULAR Revise Axial Spondyloarthritis Management Recommendations

ASAS/EULAR Revise Axial Spondyloarthritis Management Recommendations

By

Collaborative document provides guidance on non-pharmacological and pharmacological management in patients with axial spondyloarthritis.

Treatment Efficacy and Clinical Burden in Nonradiographic Axial Spondyloarthritis vs Ankylosing Spondylitis

Treatment Efficacy and Clinical Burden in Nonradiographic Axial Spondyloarthritis vs Ankylosing Spondylitis

By

New research compared treatment efficacy by drug class and clinical and humanistic burdens of nr-axSpA with those of AS.

AxSpA Therapy Can Be Guided With Predictive Modeling

AxSpA Therapy Can Be Guided With Predictive Modeling

By

Trajectory modeling of axial SpA is feasible and suggests up to a third of patents may be under-treated.

Reliability of MRI-Detected Structural Lesions for AxSpA Classification

Reliability of MRI-Detected Structural Lesions for AxSpA Classification

By

The utility of considering MRI-detected structural lesions in sacroiliac joints for the classification of patients being evaluated for axial spondyloarthritis was explored in a recent study.

Factors Predictive of Early SpA SI Joint Radiographic Progression

Factors Predictive of Early SpA SI Joint Radiographic Progression

By

Researchers sought to find the percentage of patients who will progress from nonradiographic axial SpA to radiographic axial SpA over time.

Aligning Clinical Care: Which Aspects of ASAS Do AxSpA Patients Find Most Concerning?

Aligning Clinical Care: Which Aspects of ASAS Do AxSpA Patients Find Most Concerning?

By

Findings in this study can help clinicians tailor axial spondyloarthritis clinical care appropriateiy to better address patients' needs.

Sign Up for Free e-newsletters